Message Font: Serif | Sans-Serif
No. of Recommendations: 0
Not sure what to think about TRMS. Initial Fuzeon sales were below expectations, and it looks like the stock's price over the past 5 years reflect pure hype around the drug. The only other drug in the pipeline for this small 129 employee biotech firm is a second version of Fuzeon that binds to a different area of the receptor. This drug is currently in Phase II and apparently there is not much else to help the stock recover.

It's interesting that institutions jumped on this as well following the drop. Is this a result of some "stock-picking" computers at work or is there potential upside that I'm missing?

Incidentally, there's new news on 48-week data released today:

Also, being a web developer, I have to commend them on their Fuzeon site - - although I prefer PHP, the layout is well done.


Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.